Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

Delayed Quote. Delayed  - 07/29 05:35:12 pm
98.76 EUR   -0.03%
07/26 MERCK KGAA : Biopharma Innovation Cup Honors Young Scientists
07/25 MERCK : Ethiopia Receives 14 Million Praziquantel Tablets
07/18 MERCK KGAA : Darmstadt, Germany Receives European Medicines Agency A..
News SummaryMost relevantAll newsSector news 

Merck KGaA Gives Details On Planned Efficiency Program

share with twitter share with LinkedIn share with facebook
share via e-mail
02/24/2012 | 05:51pm CEST

-- Germany's Merck provides details about efficiency program.

-- Conglomerate joins a long list of drug makers revamping themselves.

-- Merck KGaA shares fall after restructuring update.

(Adds details, share details, background.)

   By Neetha Mahadevan 

Pharmaceutical and chemical company Merck KGaA (>> Merck KGaA) said Friday it launched a cost-cutting and efficiency plan in the wake of increased price pressures in the U.S. and Europe and a series of drug development setbacks.

The company said the plan could involve job cuts across all businesses and regions to reduce costs and address "unprecedented market shifts", but it didn't disclose details, saying management still needed to speak with relevant stakeholders for a mutually acceptable solution.

"Over the next two years, Merck needs to address unprecedented market shifts, increasing competition in key product areas and existing inefficiencies in its own organization to ensure the long-term success of its business model," Chief Executive Karl-Ludwig Kley said in a statement.

With its new cost-cutting drive, the German chemical and pharmaceutical company joins a long list of other drug makers who are revamping themselves in response to falling sales and profitability.

The need to cut costs is partly due to mounting pressure stemming from health care reforms in the U.S. and Europe, where governments are increasingly reluctant to reimburse expensive drugs and advocate the use of cheaper generic medicines. Companies such as AstraZeneca Plc (AZ.LN), Novartis AG (NVS), Roche Holding AG (ROG.VX), Pfizer Inc (>> Pfizer Inc.), Eli Lilly & Co (>> Eli Lilly & Co.) have all embarked on cost saving or restructuring programs to keep costs under control.

In addition to set-backs in its drug pipeline, Merck has also been hit by a slowdown in demand at its chemicals division, which led to disappointing developments in the last year and prompted it to tighten its outlook time and again.

In the second-quarter, it recorded a 6.5% drop in revenue at its chemicals division, while in the third-quarter profits fell due largely to weakness in its performance materials division.

The efficiency measures are part of Merck's comprehensive transformation program, announced last year, and comprises two phases, the company said.

In the first two years, Merck plans to set up a new leadership organization, implement efficiency measures and focus on long-term growth, while the second phase will be focused on exploiting new growth opportunities, it added.

Merck KGaA shares fell after the news and at 1545 GMT traded down 1.2% at EUR79.70, while the DAX benchmark index traded 0.6% higher.

-By Neetha Mahadevan, Dow Jones Newswires; +49 69 2972 5507; neetha.mahadevan@dowjones.com

(Sten Stovall contributed to this article.)

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK KGAA
07/28 MERCK KGAA : MilliporeSigma Starts Construction on $115 Million Multi-faceted Li..
07/26 MERCK KGAA : Biopharma Innovation Cup Honors Young Scientists
07/25 MERCK : Ethiopia Receives 14 Million Praziquantel Tablets
07/25 MERCK : Ethiopia Receives 14 Million Praziquantel Tablets Around 23% of Ethiopia..
07/18 MERCK KGAA : Darmstadt, Germany Receives European Medicines Agency Acceptance fo..
07/14 MERCK KGAA : EMD Serono Commits EUR1.5 million to the Grant for Fertility Innova..
07/14 MERCK KGAA : Recent Findings from Merck KGaA Provides New Insights into Fenofibr..
07/13 MERCK KGAA : Advances Water Purification Systems with New High-Throughput Line
07/12 MERCK KGAA : Expands Excipients Portfolio, Adding Polymers for Sustained Release..
07/11 MERCK : and University of Nairobi to Start Medical Oncology Fellowship Program
More news
Sector news : Specialty & Advanced Pharmaceuticals
08:48aDJMERCK : Earnings Watch -- WSJ
01:14a BAYER : says will halt future U.S. sales of insecticide
07/29DJTech Stocks Up On Google Earnings - Tech Roundup
07/29DJMERCK : Revenue Rises on Cancer, Hepatitis Treatments -- Update
07/29DJABBVIE : Results Boosted by Humira, Pipeline Growth
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
07/18 Merck's marketing application for Cladribine tablets accepted for review in E..
07/06 Late-stage study commences assessing Merck KGaA and Pfizer's avelumab + chemo..
07/05 OneCrinone reproductive treatment approved in Japan
06/24 Sector Licks Its Brexit Wounds
06/24 Eylea Combinations And Array's Play For Melanoma
Financials (€)
Sales 2016 15 088 M
EBIT 2016 3 263 M
Net income 2016 1 669 M
Debt 2016 10 865 M
Yield 2016 1,23%
P/E ratio 2016 24,80
P/E ratio 2017 23,13
EV / Sales 2016 1,57x
EV / Sales 2017 1,40x
Capitalization 12 764 M
More Financials
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 99,8 €
Spread / Average Target 1,1%
Consensus details
EPS Revisions
More Estimates Revisions
Stefan Oschmann Chief Executive Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Laszlo Radvanyi Senior Vice President & Head-Research
Crocifissa Attardo Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA10.26%14 264
ABBVIE INC11.80%107 118
BIOGEN INC-5.36%63 530
KYOWA HAKKO KIRIN CO L..-5.35%10 181
More Results